Radiation Therapy Planning Using Fibroblast Activation Protein Inhibitor

Stefan A Koerber

doi:10.1016/j.cpet.2023.03.003

Radiation Therapy Planning Using Fibroblast Activation Protein Inhibitor

PET Clin. 2023 Jul;18(3):369-380. doi: 10.1016/j.cpet.2023.03.003. Epub 2023 Apr 26.

Author

Stefan A Koerber¹

Affiliation

¹ Department of Radiation Oncology, Heidelberg University Hospital, Heidelberg, Germany; Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany; Department of Radiation Oncology, Barmherzige Brueder Hospital Regensburgh, Regensburg, Germany. Electronic address: stefan.koerber@med.uni-heidelberg.de.

PMID: 37117122
DOI: 10.1016/j.cpet.2023.03.003

Abstract

Computed tomography (CT), MR imaging, and PET with fluorodeoxyglucose F18/CT are commonly used for radiation therapy planning; however, issues including precise nodal staging on CT or false positive results on PET/CT limit their usability. Clinical trials using fibroblast activation protein ligands for additional imaging have provided promising results regarding staging and target volume delineation-particularly suitable for sarcoma, some gastrointestinal tumors, head and neck tumors, and lung and pancreatic cancer. Although further prospective trials are necessary to identify clinical settings for its application in radiation oncology, fibroblast activation protein inhibitor PET/CT indisputably represents an excellent opportunity for assisting radiotherapy planning.

Keywords: FAPI-PET/CT; Oncologic management; Radiation oncology; Treatment planning.

Publication types

Review

MeSH terms

Humans
Neoplasms* / radiotherapy
Positron Emission Tomography Computed Tomography / methods
Protease Inhibitors* / metabolism
Radiotherapy* / methods
Radiotherapy* / standards
Radiotherapy* / trends

Substances

Protease Inhibitors